7 Factors Fueling The Growth Of Oncology Trials In Asia-Pacific

By Rupa Doshi and Ashish Jain

Oncology clinical trial activity in the Asia-Pacific (APAC) region has been robust over the past decade, increasing 138 percent from 2010 to 2020.¹ In the past, most studies conducted in APAC countries were later studies, but there has recently been an uptick in the number of phase 1 trials. This bustling activity, in combination with the fastest growing global market for pharmaceutical sales, makes the APAC region an attractive target market for clinical trials and commercialization.

In this blog post, we highlight seven factors contributing to oncology clinical trial activity in the APAC region.